SBH Leadership
Raphael Nir, PhD
President & Chief Scientific Officer
Dr. Raphael Nir has served as President and Chief Scientific Officer of SBH Sciences since co-founding the company in 1997. He started SBH Sciences to fulfill his dream of becoming a key player in the biotech arena, and to help companies develop drugs. Under his management, SBH Sciences has become a leading supplier of recombinant cytokines and a preferred discovery research service provider.
Raphael is an ambitious entrepreneur and has co-founded seven additional biotech and diagnostics companies: Karyopharm Therapeutics, SBH Diagnostics, Woodland Biosciences, Galectin Sciences, Alma Bio Therapeutics, Vuja De Sciences and NeuroDex. To fulfill his vision and help startup companies, he co-founded two additional companies; Sky Ventures and ABI-LAB; a 7-year old bioincubator located in Natick, MA, currently housing 45 biotechnology companies.
Prior to SBH Sciences formation, Raphael earned his Ph.D. in biotechnology as well as a M.S. in biochemistry, and a B.S. in chemistry from Tel-Aviv University. His postdoctoral research was at Schering Plough Research Institute where he later became a Senior Scientist/Associate Principal Scientist and developed innovative cell culture processes and solutions related to biological production. Additionally, he earned a M.S. in engineering management from New Jersey Institute of Technology (1997).
Tami Rashal, M.D., MBA
Chief Medical Officer
Tami Rashal, M.D., is the Chief Medical Officer of SBH Sciences, where she joined to support Dr. Raphael Nir’s vision to become a key player in the biotechnology industry. With over a decade of experience in clinical trial management and early-stage drug discovery, Dr. Rashal has successfully navigated multiple IND and NDA submissions, demonstrating her deep expertise in bringing novel therapies to patients.
Dr. Rashal is a seasoned hematologist-oncologist and entrepreneur with a proven track record of leading medical development companies at various stages of growth. Her experience also includes the successful management of Merlin, an AI-based clinical trial decision-making tool, which will play a key role in advancing SBH Sciences’ portfolio companies.
Dr. Rashal’s deep understanding of the oncology landscape, combined with her passion for advancing drug development and clinical research, will be invaluble to SBH Sciences and its Bioventure initiatives. Dr. Rashal earned her M.D. in Medicine from Semmelweis University and an MBA in Health Care Administration from Tel Aviv University. She completed her internal medicine training at Sheba Medical Center (Tel Hashomer) and her hematology-oncology fellowship at Sourasky Medical Center (Ichilov).
Adam Nir
Chief Diagnostic Officer
Adam Nir serves as the Chief Diagnostic Officer at SBH Sciences, bringing over a decade of expertise in biomarker analysis and diagnostic testing. He leads the biomarker department with precision, overseeing the seamless execution of complex, high-impact projects that drive scientific advancements. His extensive knowledge in ELISA development, multiplex analysis, and automated Western technology enables SBH Sciences to deliver cutting-edge, reproducible results that support breakthrough discoveries.
In 2024, Adam and his team provided expert biomarker analysis and diagnostic support to over 40 biotech companies, ensuring the highest standards of accuracy and reliability. Under his leadership, the laboratory adheres to Good Laboratory Practice (GLP) guidelines, maintaining the integrity and reproducibility of all data. Adam plays a pivotal role in strategic client support, offering comprehensive data analysis, optimizing project workflows, and providing scientific guidance that drives innovation.
Adam holds a Master of Arts in International Relations and a Master of Strategic Studies from Tel Aviv University (2013), along with dual Bachelor of Arts (B.A.) degrees in Biochemistry and Political Science from Brandeis University (2006).